









Markets
/
Stocks
/
nasdaq-blfs
/

BioLife Solutions Inc

BLFS

22.430USD

+0.410+1.86%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.08BMarket Cap

LossP/E TTM



BioLife Solutions Inc

22.430

+0.410+1.86%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of BioLife Solutions Inc

Currency: USD Updated: 2026-02-06

Key Insights

BioLife Solutions Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 19 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 32.22.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

BioLife Solutions Inc's Score

Industry at a Glance

Industry Ranking

19 / 205

Overall Ranking

99 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

BioLife Solutions Inc Highlights

StrengthsRisks

BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.

Growing

The company is in a growing phase, with the latest annual income totaling USD 82.25M.

Undervalued

The company’s latest PE is -404.36, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 49.86M shares, decreasing 1.47% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 82.95K shares of this stock.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

32.222

Target Price

+42.14%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of BioLife Solutions Inc is 8.56, ranking 37 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 28.07M, representing a year-over-year decrease of 8.19%, while its net profit experienced a year-over-year decrease of 136.47%.

Score

Industry at a Glance

Previous score

8.56

Change



Financials

8.66

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

9.23

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.67

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.24

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

BioLife Solutions Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of BioLife Solutions Inc is 7.43, ranking 88 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -404.36, which is -99.06% below the recent high of -3.78 and -20.33% above the recent low of -486.57.

Score

Industry at a Glance

Previous score

7.43

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 19/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of BioLife Solutions Inc is 8.40, ranking 32 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 32.00, with a high of 34.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

8.40

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

32.222

Target Price

+42.14%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

114

Total

Median

Average

Company name

Ratings

Analysts

BioLife Solutions Inc

BLFS

Stryker Corp

SYK

Abbott Laboratories

ABT

Medtronic PLC

MDT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of BioLife Solutions Inc is 6.75, ranking 92 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 25.53 and the support level at 20.34, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.45

Change

0.3

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.381

Sell

RSI(14)

39.409

Neutral

STOCH(KDJ)(9,3,3)

20.595

Neutral

ATR(14)

1.164

Low Volatility

CCI(14)

-82.074

Neutral

Williams %R

79.191

Sell

TRIX(12,20)

-0.409

Sell

StochRSI(14)

82.403

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

22.458

Sell

MA10

22.953

Sell

MA20

23.833

Sell

MA50

24.679

Sell

MA100

25.537

Sell

MA200

24.314

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of BioLife Solutions Inc is 10.00, ranking 1 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 109.33%, representing a quarter-over-quarter decrease of 3.02%. The largest institutional shareholder is The Vanguard, holding a total of 3.08M shares, representing 6.40% of shares outstanding, with 8.79% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Casdin Capital, LLC

5.96M

-11.18%

T. Rowe Price Investment Management, Inc.

4.07M

-4.24%

BlackRock Institutional Trust Company, N.A.

5.10M

+0.42%

Invesco Advisers, Inc.

3.48M

+0.62%

The Vanguard Group, Inc.

Star Investors

2.96M

+2.43%

State Street Investment Management (US)

1.46M

+3.38%

Fred Alger Management, LLC

1.11M

-11.15%

Fidelity Management & Research Company LLC

1.02M

+35792.97%

Rockefeller Capital Management

1.01M

-1.59%

MFS Investment Management

1.10M

-0.43%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of BioLife Solutions Inc is 6.45, ranking 60 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.92. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.